High Revenue Growth Stocks in Health Care
Companies with year-over-year revenue growth exceeding 10%, indicating meaningful business expansion.
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
91 Companies Meeting Criteria
Showing 1–50 of 91 companies, ranked by Revenue Growth.
| # | Company | Revenue Growth | Revenue |
|---|---|---|---|
| 1 | XENEXenon Pharmaceuticals Inc. | 763.9% | $311,000 |
| 2 | NUVBNuvation Bio Inc. | 699.0% | $8M |
| 3 | IBRXImmunityBio, Inc. | 668.3% | $15M |
| 4 | CRNXCrinetics Pharmaceuticals, Inc. | 640.7% | $1M |
| 5 | SNDXSyndax Pharmaceuticals Inc | 627.8% | $24M |
| 6 | AVDLAVADEL PHARMACEUTICALS PLC | 504.8% | $169M |
| 7 | MDGLMADRIGAL PHARMACEUTICALS, INC. | 432.1% | $180M |
| 8 | STOKStoke Therapeutics, Inc. | 404.5% | $37M |
| 9 | CYTKCytokinetics | 376.6% | $18M |
| 10 | IONSIONIS PHARMACEUTICALS INC | 316.5% | $705M |
| 11 | SLSSELLAS Life Sciences Group, Inc. | 300.0% | $0 |
| 12 | KALVKalVista Pharmaceuticals, Inc. | 294.0% | $13M |
| 13 | PRAXPraxis Precision Medicines, Inc. | 249.5% | $9M |
| 14 | PHATPhathom Pharmaceuticals, Inc. | 216.9% | $55M |
| 15 | URGNUroGen Pharma Ltd. | 186.4% | $90M |
| 16 | ABCLAbCellera Biologics Inc. | 160.6% | $29M |
| 17 | ANABANAPTYSBIO, INC | 157.0% | $91M |
| 18 | TARSTarsus Pharmaceuticals, Inc. | 146.7% | $183M |
| 19 | SLNOSOLENO THERAPEUTICS INC | 138.8% | $1M |
| 20 | MGTXMeiraGTx Holdings plc | 137.4% | $33M |
| 21 | ABUSArbutus Biopharma Corp | 128.2% | $6M |
| 22 | BBIOBridgeBio Pharma, Inc. | 126.3% | $222M |
| 23 | BEAMBeam Therapeutics Inc. | 120.0% | $64M |
| 24 | CNTACentessa Pharmaceuticals plc | 118.9% | $0 |
| 25 | PTCTPTC Therapeutics, Inc. | 114.5% | $807M |
| 26 | TVTXTravere Therapeutics, Inc. | 110.5% | $233M |
| 27 | RGNXREGENXBIO Inc. | 104.5% | $83M |
| 28 | ARQTArcutis Biotherapeutics, Inc. | 91.3% | $197M |
| 29 | TGTXTG Therapeutics, Inc. | 87.3% | $329M |
| 30 | SRRKScholar Rock Holding Corp | 76.4% | $33M |
| 31 | RNAAvidity Biosciences, Inc. | 72.1% | $11M |
| 32 | TBPHTheravance Biopharma, Inc. | 66.9% | $64M |
| 33 | INSMINSMED Inc | 66.7% | $364M |
| 34 | AXSMAxsome Therapeutics, Inc. | 65.5% | $386M |
| 35 | PVLAPALVELLA THERAPEUTICS, INC. | 65.3% | $43M |
| 36 | ALNYALNYLAM PHARMACEUTICALS, INC. | 65.2% | $2.2B |
| 37 | NVAXNOVAVAX INC | 64.7% | $682M |
| 38 | RIGLRIGEL PHARMACEUTICALS INC | 64.1% | $179M |
| 39 | IOVAIOVANCE BIOTHERAPEUTICS, INC. | 60.6% | $164M |
| 40 | LGNDLigand Pharmaceuticals, Inc. | 60.4% | $251M |
| 41 | KNSAKiniksa Pharmaceuticals International, plc | 60.1% | $423M |
| 42 | PRMEPrime Medicine, Inc. | 55.3% | $3M |
| 43 | ADPTAdaptive Biotechnologies Corp | 54.8% | $179M |
| 44 | MIRMMirum Pharmaceuticals, Inc. | 54.7% | $337M |
| 45 | NRIXNurix Therapeutics, Inc. | 54.0% | $84M |
| 46 | RLAYRelay Therapeutics, Inc. | 53.4% | $10M |
| 47 | NBYNovaBay Pharmaceuticals, Inc. | 53.2% | $18M |
| 48 | TNGXTango Therapeutics, Inc. | 48.3% | $42M |
| 49 | AGIOAGIOS PHARMACEUTICALS, INC. | 48.0% | $36M |
| 50 | RYTMRHYTHM PHARMACEUTICALS, INC. | 45.8% | $130M |
Understanding Revenue Growth
Revenue growth above 10% is considered strong for large-cap companies. It typically signals increasing demand, successful new products, or geographic expansion. Growth rates are calculated from the two most recent annual SEC filings. One-time events like acquisitions can inflate growth temporarily.
YoY Revenue Growth > 10%
Results are based on SEC EDGAR filings. Companies with missing, unreliable, or extreme outlier values are excluded from screening.
Related Rankings
See the top companies ranked by these related metrics